Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas

Brain Pathology

Volumn 10, Issue 2, 2000, Pages 249-259

  Sung, Tammy ^a   Miller, Douglas C ^a,c   Hayes, Roberta L ^b   Alonso, Michelle ^a   Yee, Herman ^a,c   Newcomb, Elizabeth W ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADOLESCENT; ARTICLE; ASTROCYTOMA; CANCER GENETICS; CANCER GRADING; CHILD; CHILDHOOD CANCER; CHROMOSOME 10Q; CHROMOSOME 9P; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0034079777     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2000.tb00258.x     Document Type: Article

References (54)

1. Baswlga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831
2. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H (1997) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185
3. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H (1997) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94: 303-309
4. Bostrom J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G (1998) Mutation of the PTEN(MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29-33
5. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN (1998) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57: 122-130
6. Cheng Y, Ng H-K, Ding M, Zhang S-F, Pang J C-S, Lo K-W (1999) Molecular analysis of microdissected ate novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 58: 120-128
7. Cheng Y, Ng H-K, Zhang S-F, Ding M, Pang JC-S, Zheng J, Poon WS (1999) Genetic alterations in pediatric high-grade astrocytomas. Human Pathol 30; 1284-1290
8. Dohrmann GJ, Farwell JR, Flannery JT (1975) Glioblastoma in children. J Neurosurg 44: 442-448
9. Duerr E-M, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Persons R, Eng C, von Deimling A (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16: 2259-2264
10. Felix CA, Slave I, Dunn M, Strauss EA, Phillips PC, Rorke LB, Sutton L, Bunin GR, Biegel JA (1995) p53 gene mutations in pediatric brain tumors. Med Ped Oncol 25: 431-436
11. Frankel RH, Bayona W, Koslow M, Newcomb EW (1992) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52: 1427-1433
12. Freedman D, Levine AJ (1999) Regulation of the p53 protein by the MDM2 oncoprotein-Thirty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 59: 1-7
13. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM (1992) p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52: 674-679
14. Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis, Field JK, Kittas C (1998) Alterations of the p16-Rb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: Relationship with p53 and MDM2 protein expression. Am J Pathol 153: 1749-1765
15. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871-875
16. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS, James CD (1994) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807
17. He J, Reifenberger G, Liu L, Collins VP, James CD (1994) Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosome Cancer 11: 91-96
18. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208
19. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK (1997) Glioblastoma. In: Pathology and Genetics of Tumours of the Nervous System. Kleihues P, Cavenee WK (eds.), IARC Press, Lyon, pp 16-24
20. Kleihues P, Burger PC, Scheithauer BW (1993) Histological Typing of Tumors of the Central Nervous System. Springer-Verlag Berlin, Heidelberg, New York
21. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E (1997) MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75: 1269-1278
22. Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436
23. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb, EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9: 949-954
24. Litofsky NS, Hinton D, Raffel C (1994) The lack of a role for p53 in astocytomas in pediatric patients. Neurosurgery 34: 967-973
25. Louis DN, Rubio M-P, Correa KM, Gusella JF, von Deimling A (1993) Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 52: 507-515
26. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. (1998) Tumors of central neuroepithelial origin. In: Russell and Rubinstein's Pathology of Tumors of the Nervous System, 6th Ed. Bigner DD, McLendon RE, Bruner JM, (eds), pp. 337-338, Arnold:London
27. Moscatello DK, Ramirez G, Wong AJ (1997) A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57: 1419-1424
28. Newcomb EW, Cohen C, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8: 655-667
29. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235
30. Orellana C, Hernandez-Marti M, Marinez F, Castel V, Millan JM, Alvarez-Garijo JA, Prieto F, Badia L (1998) Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations. Cancer Genet Cytogenet 102: 93-99
31. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-1/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251
32. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57: 304-309
33. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723
34. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
35. Rainov NG, Dobberstein K-U, Bahn H, Holzhausen H-J, Lauten-Schlager C, Heidecke V, Burkert W (1997) Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28
36. Rao LS, Miller DC, Newcomb EW (1997) A correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4 genes in astrocytomas. Diag Mol Pathol 6: 15-122
37. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330
38. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of MDM2 gene in a subset of human ma ignant gliomas without p53 mutations. Cancer Res 53: 2736-2739
39. Schlott T, Reimer S, Jahns A. Ohlenbusch A, Ruschenburg I, Nagel H, Droese M (1997) Point mutation and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J Pathol 182: 54-61
40. Soong R, lacopetta BJ (1997) A rapid and nonisotopic method for screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 10: 252-258
41. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15: 356-362
42. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME (1997) Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56: 782-789
43. Teng D H-F, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WKA, Fujii G, Berson Am Bookstein R, Bolen JB, Tavtigian SV, Steck PA (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221-5225
44. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, YonekawaY, Kleihues P, Ohgaki H (1998) PTEN(MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684-689
45. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153
46. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestler OD, Seizinger BR (1992) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77: 295-301
47. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26
48. Wang SI, Puc J, Li J, Bruce JN, Cairns P Sidransky D, Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183-4186
49. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1997) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224
50. Wu X, Bayle H, Olson D, Levine AJ (1993) The p53-mdm-2 autoregulatory feedback loop. Genes & Develop 7: 1126-1132
51. Yang X-D, Jia X-C, Corvalan RF, Wang P, Davis CG, Jakobovits A (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236-1243
52. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734
53. Zhang S, Feng X, Koga H, Ichikawa T, Abe S, Kumanishi T (1993) p53 gene mutations in pontine gliomas of juvenile onset. Biochem Biophys Res Commun 196: 851-857
54. Zar, JH (1984) Biostatistical Analysis. Prentice-Hall, Inc., Englewood Cliffs, NJ